



11 February 2015

**High Concentration of Shareholding
in
Yestar International Holdings Company Limited (Stock Code: 02393)**

This announcement is made by the Securities and Futures Commission (“SFC”) in respect of the concentration of the shareholding of Yestar International Holdings Company Limited (“the Company”) in the hands of a limited number of shareholders as at 27 January 2015.

In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the shares of the Company (“Shares”) could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.

The SFC has recently completed an enquiry into the shareholding of the Company. Our findings suggested that as at 27 January 2015, 16 shareholders held an aggregate of 392,171,588 Shares, representing 21.00% of the issued Shares. Such shareholding, together with 1,327,185,000 Shares (representing 71.07% of the issued Shares) held by 4 substantial shareholders of the Company, represented 92.07% of the issued Shares as at 27 January 2015. Therefore only 148,143,412 Shares (representing 7.93% of the issued Shares) were held by other shareholders.

As at 27 January 2015, the shareholding structure of the Company was as follows:-

	Number of Shares held (Shares)	% of total number of issued Shares (%)
Jeane Hartono (Note 1)	676,890,000	36.25
James Hartono (Note 1)	265,410,000	14.21
Rico Hartono (Note 1)	265,410,000	14.21
Chen Chen Irene Hartono (Note 1)	119,475,000	6.40
A group of 16 shareholders	392,171,588	21.00
Other shareholders	148,143,412	7.93
Total	<u>1,867,500,000</u>	<u>100.00</u>

Note 1: Ms. Jeane Hartono, Mr. Rico Hartono and Ms. Chen Chen Irene Hartono are all siblings of Mr. James Hartono, the Chairman and Executive Director of the Company.



The Company was listed on the Main Board of the Stock Exchange of Hong Kong Limited on 11 October 2013 by way of global offering of 450,000,000 Shares, representing 25.00% of the issued Shares, at an initial public offer (“IPO”) price of HK\$0.345 per Share (*Note 2*). The share price closed at HK\$0.395 on its first day of listing, 14.49% higher than the IPO price.

Subsequently, the closing price of the Shares increased 554.43% from HK\$0.395 on 11 October 2013 to HK\$2.585 on 17 November 2014 and then decreased to HK\$1.80 on 14 January 2015.

On 15 January 2015, the Company announced a positive profit alert stating that it was expected to record an increase of not less than 40% in its consolidated net profit for the year ended 31 December 2014 as compared with that of the year ended 31 December 2013.

On 26 January 2015, the Company announced that it is in a preliminary stage of considering the feasibility of an acquisition of a company which is principally engaged in the medical in vitro diagnostic industry in the PRC, which is subject to further negotiation and the results of due diligence, which may or may not materialize.

As at 10 February 2015, the Shares closed at HK\$2.43, representing an increase of 35.00% from 14 January 2015 or an increase of 515.19% since its first day of listing.

Note 2: The original IPO price was HK\$1.38. All prices and share quantity above have been adjusted for a 1-to-4 Share subdivision which was effective on 16 December 2014.

In view of the high concentration of shareholding in a small number of shareholders, shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of shares traded, and should exercise extreme caution when dealing in the Shares.

End